Last reviewed · How we verify
Placebo for Pancrease MT 10.5 or MT 21
This is a placebo, meaning it has no active therapeutic effect.
This is a placebo, meaning it has no active therapeutic effect. Used for Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
At a glance
| Generic name | Placebo for Pancrease MT 10.5 or MT 21 |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not interact with any biological systems or molecules. It is used as a control in clinical trials to compare the efficacy of active treatments.
Approved indications
- Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: